NCT04282980 - A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

February 26, 2021

Study Completion Date

August 23, 2022

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG

DCC-2618

Oral kinase inhibitor

Trial Locations (9)

Beijing Cancer Hospital, Beijing

Chinese People's Liberation Army General Hospital, Beijing

Union Medical College Hospital, Chongqing Medical University, Chongqing

Union Medical College Hospital, Fujian Medical University, Fuzhou

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

Fudan University Cancer Hospital, Shanghai

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY